ClinicalTrials.gg
CompletedNCT01115738Updated Nov 20, 2012Results posted

Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

A Phase 2 interventional study of Prasugrel and Clopidogrel in Acute Coronary Syndrome, sponsored by Eli Lilly and Company. Completed at 3 sites in India. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-11-20.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clopidogrel in Acute Coronary Syndrome — 3 open to participants now, 3 under way, none of them phase 3. Clopidogrel · Acute Coronary Syndrome.

Enrollment
13th of 33
282 · median 200
Started
2010
with 3 others
Phase 2
5 of 34
1 open now
Registered
8th of 34
by date

Among the 34 studies testing clopidogrel in Acute Coronary Syndrome, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2010, is one of 5 in phase 2, and was the 8th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

3 of the 34 studies testing clopidogrel in Acute Coronary Syndrome are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clopidogrel in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on platelet inhibition in patients presenting with acute coronary syndrome (ACS). Platelet inhibition following a prasugrel LD in clopidogrel pretreated patients' will be determined in a time-dependent manner for two different prasugrel loading doses (30 mg and 60 mg). Understanding the effects of this combination on platelet inhibition will provide guidance to physicians on the use of prasugrel in patients who have already been pretreated with clopidogrel.

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Plavix, Effient
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants hospitalized with acute coronary syndrome (ACS) [unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)] as determined by the investigator, and who are anticipated to undergo percutaneous coronary intervention (PCI) as a treatment for the ACS event within 24 hours of the clopidogrel/placebo loading dose
  • Participants provide signed form (ICF)
  • Participants weigh at least 60 kilograms (kg) at the time of screening
  • Women of (that is, women who are not surgically or chemically sterilized and who are between menarche and 1-year ), test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Have cardiogenic shock at the time of randomization (systolic blood pressure greater than 90 millimeters of mercury (mm Hg) associated with clinical evidence of end-organ hypoperfusion, or participants requiring vasopressors to maintain systolic blood pressure over 90 mm Hg and associated with clinical evidence of end-organ hypoperfusion
  • Have ventricular arrhythmias
  • Have (NYHA) Class IV congestive heart failure
  • Have systolic blood pressure greater than 180 mm Hg, or diastolic blood pressure greater than 100 mm Hg on more than 1 assessment at any time from participant presentation of ACS treatment to enrollment
  • Have received fibrin-specific fibrinolytic therapy less than 24 hours prior to randomization
  • Have received nonfibrin-specific fibrinolytic therapy less than 48 hours prior to randomization
  • Have active internal bleeding or history of bleeding diathesis
  • Have clinical findings, in the judgment of the investigator, associated with an increased risk of bleeding
  • Prior history of ischemic or hemorrhagic stroke
  • Intracranial neoplasm, arteriovenous malformation, or aneurysm
  • Prior history of (TIA)
  • Have an (INR) known to be greater than 1.5 at the time of evaluation
  • Have a count of less than 100,000 per cubic millimeter (mm\^3) at the time of evaluation
  • Have anemia [ (Hgb) less than 10 grams per deciliter (g/dL)] at the time of evaluation
  • Have received 1 or more doses of a thienopyridine (ticlopidine, clopidogrel, or prasugrel) or other adenosine diphosphate (ADP) receptor inhibitor within 10 days prior to screening
  • Have been administered glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor within the past 7 days or planned use of a GPIIb/IIIa inhibitor during PCI
  • Are receiving or will receive oral anticoagulation or other antiplatelet therapy, other than aspirin (ASA), which cannot be safely discontinued for the duration of the study.
  • Are receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued during the study
  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have previously completed or withdrawn from this study or any other study investigating prasugrel
  • Are women who are known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding
  • Have a concomitant medical illness (for example, terminal ) that in the opinion of the investigator, is associated with reduced survival over the expected treatment period
  • Have known severe hepatic dysfunction (that is, with cirrhosis or portal hypertension)
  • Have a history of intolerance or allergy to aspirin or approved thienopyridines (ticlopidine, clopidogrel or prasugrel)
  • May be unable to cooperate with protocol requirements and follow-up procedures
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
282 participants (actual)

Study arms

  • Placebo comparator
    Placebo and 60 milligram (mg) Prasugrel

    Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

    Drug: Prasugrel · Drug: Placebo

  • Experimental
    600 mg Clopidogrel and 60 mg Prasugrel

    600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

    Drug: Prasugrel · Drug: Clopidogrel

  • Experimental
    600 mg Clopidogrel and 30 mg Prasugrel

    600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

    Drug: Prasugrel · Drug: Clopidogrel

Interventions

  • Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.

    Also known as: LY640315

  • Loading dose administered once orally.

  • DrugPlacebo

    Loading dose administered once orally

06

What researchers measure

Primary outcomes

  1. Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD)

    ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.

    Time frame: 6 hours after prasugrel loading dose

Secondary outcomes

  1. Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation at Baseline, 2, 24 and 72 Hours After Prasugrel Loading Dose (LD)

    ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.

    Time frame: Baseline and 2 hours and 24 hours and 72 hours after prasugrel loading dose

  2. Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit

    Time frame: Baseline, 72 hours

  3. Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin

    Time frame: Baseline, 72 hours

  4. Percentage of Inhibition of Platelet Aggregation

    Adenosine Diphosphate (ADP)-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. The internal BASE standard is an independent measurement and serves as an estimate of the participant's baseline platelet aggregation independent of P2Y12 receptor inhibition. Percent Inhibition of Platelet Aggregation=(1-\[PRU/BASE) x 100%, high numbers represent increased platelet inhibition. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.

    Time frame: Baseline and 2 and 6 and 24 and 72 hours after loading dose

  5. Percentage of Poor Responders

    Poor responders are those who had P2Y12 Reaction Units (PRU)≥ 240.

    Time frame: Baseline and 2 and 6 and 24 and 72 hours after loading dose

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    TEAE is a worsening or new occurrence of adverse event (AE) during treatment compared to baseline. A summary of serious adverse events (SAE) and other nonserious AE are located in the Reported Adverse Events section.

    Time frame: Baseline through 72 hours after prasugrel loading dose

  7. P2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM)

    CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.

    Time frame: Baseline

  8. P2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM)

    CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.

    Time frame: 6 hours after prasugrel loading dose

07

Results

Posted Oct 26, 2012

Participant flow

Participant flow — Overall Study
MilestonePlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Started1108389
Received any treatment1097988
Pharmacodynamic (pd) population524750
Completed856262
Not completed252127
Withdrew: Death100
Withdrew: Lost to follow-up001
Withdrew: Physician decision181517
Withdrew: Withdrawal by subject669

Outcome measures

PrimaryAdenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD)

ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.

Time frame:
6 hours after prasugrel loading dose
Reported as:
Least squares mean · PRU
Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD)
PRUPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD)57.86 ± 11.8635.61 ± 12.3653.92 ± 11.74
Statistical analysis
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.188 (P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 22.24 · 95% CI -10.98 to 55.47Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.809 (P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 3.93 · 95% CI -28.20 to 36.07Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
SecondaryAdenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation at Baseline, 2, 24 and 72 Hours After Prasugrel Loading Dose (LD)

ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.

Time frame:
Baseline and 2 hours and 24 hours and 72 hours after prasugrel loading dose
Reported as:
Least squares mean · PRU
Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation at Baseline, 2, 24 and 72 Hours After Prasugrel Loading Dose (LD)
PRUPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Baseline265.51 ± 13.01248.58 ± 13.99229.62 ± 13.38
2 Hours after Prasugrel LD122.55 ± 17.28113.10 ± 18.07117.10 ± 17.47
24 Hours after Prasugrel LD62.73 ± 10.4334.05 ± 10.8851.43 ± 10.72
72 Hours after Prasugrel LD56.95 ± 8.4048.08 ± 9.0960.29 ± 9.05
Statistical analysis
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.370 (P-value is for Baseline. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 16.93 · 95% CI -20.26 to 54.12Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.052 (P-value is for Baseline. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 35.89 · 95% CI -0.29 to 72.06Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.703 (P-value is for 2 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 9.45 · 95% CI -39.55 to 58.45Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.823 (P-value is for 2 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 5.45 · 95% CI -42.53 to 53.44Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.054 (P-value is for 24 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 28.69 · 95% CI -0.47 to 57.84Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.436 (P-value is for 24 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 11.30 · 95% CI -17.29 to 39.90Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.463 (P-value is for 72 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 8.87 · 95% CI -14.96 to 32.71Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.777 (P-value is for 72 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -3.34 · 95% CI -26.62 to 19.94Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
SecondaryMean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit
Time frame:
Baseline, 72 hours
Reported as:
Mean · proportion of 1.0
Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit
proportion of 1.0Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit0.0 ± 0.040.0 ± 0.030.0 ± 0.03
SecondaryMean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin
Time frame:
Baseline, 72 hours
Reported as:
Mean · gram per deciliter (g/dL)
Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin
gram per deciliter (g/dL)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin-0.9 ± 1.41-0.6 ± 1.03-0.6 ± 1.04
SecondaryPercentage of Inhibition of Platelet Aggregation

Adenosine Diphosphate (ADP)-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. The internal BASE standard is an independent measurement and serves as an estimate of the participant's baseline platelet aggregation independent of P2Y12 receptor inhibition. Percent Inhibition of Platelet Aggregation=(1-\[PRU/BASE) x 100%, high numbers represent increased platelet inhibition. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.

Time frame:
Baseline and 2 and 6 and 24 and 72 hours after loading dose
Reported as:
Least squares mean · percentage of inhibition
Percentage of Inhibition of Platelet Aggregation
percentage of inhibitionPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Baseline9.71 ± 3.4413.02 ± 3.7014.94 ± 3.54
2 Hours after Prasugrel LD56.04 ± 5.8858.75 ± 6.1654.89 ± 5.95
6 Hours after Prasugrel LD79.87 ± 3.9586.77 ± 4.1378.55 ± 3.93
24 Hours after Prasugrel LD77.57 ± 3.5687.64 ± 3.7478.56 ± 3.68
72 Hours after Prasugrel LD78.48 ± 2.9583.51 ± 3.2878.17 ± 3.27
Statistical analysis
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.505 (P-value is for Baseline. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -3.31 · 95% CI -13.10 to 6.48Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.278 (P-value is for Baseline. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -5.23 · 95% CI -14.74 to 4.27Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.749 (P-value is for 2 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -2.71 · 95% CI -19.44 to 14.02Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.890 (P-value is for 2 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 1.15 · 95% CI -15.24 to 17.53Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.223 (P-value is for 6 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -6.89 · 95% CI -18.02 to 4.24Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.808 (P-value is for 6 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 1.33 · 95% CI -9.44 to 12.10Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.049 (P-value is for 24 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -10.07 · 95% CI -20.11 to -0.04Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.842 (P-value is for 24 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Median difference (final values): -0.99 · 95% CI -10.85 to 8.86Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 60-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.247 (P-value is for 72 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): -5.03 · 95% CI -13.58 to 3.52Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
  • Placebo and 60-mg Prasugrel vs 600-mg Clopidogrel and 30-mg Prasugrel · Mixed Model Repeated Measures Analysis · p = 0.942 (P-value is for 72 hours after prasugrel LD. P-values were not adjusted for multiplicity. P-values \<0.05 were considered statistically significant.) · Mean difference (final values): 0.31 · 95% CI -8.09 to 8.71Fixed effects were Treatment, Visit, Country, Treatment-by-Visit. Participants and Error were Random Effects. Covariance structure was Unstructured.
SecondaryPercentage of Poor Responders

Poor responders are those who had P2Y12 Reaction Units (PRU)≥ 240.

Time frame:
Baseline and 2 and 6 and 24 and 72 hours after loading dose
Reported as:
Number · percentage of participants
Percentage of Poor Responders
percentage of participantsPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Baseline68.166.751.2
2 Hours after Prasugrel LD23.312.821.4
6 Hours after Prasugrel LD11.65.34.4
24 Hours after Prasugrel LD9.52.98.8
72 Hours after Prasugrel LD000
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

TEAE is a worsening or new occurrence of adverse event (AE) during treatment compared to baseline. A summary of serious adverse events (SAE) and other nonserious AE are located in the Reported Adverse Events section.

Time frame:
Baseline through 72 hours after prasugrel loading dose
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Serious Adverse Events281
Nonserious Adverse Events373131
SecondaryP2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM)

CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.

Time frame:
Baseline
Reported as:
Least squares mean · PRU
P2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM)
PRUClopidogrel at Baseline -CYP2C19 EMClopidogrel at Baseline - CYP2C19 RM
P2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM)243.549 ± 11.244240.100 ± 17.955
Statistical analysis
  • Clopidogrel at Baseline -CYP2C19 EM vs Clopidogrel at Baseline - CYP2C19 RM · ANOVA · p = 0.8711 · Mean difference (final values): 3.449 · 95% CI -38.81 to 45.71
SecondaryP2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM)

CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.

Time frame:
6 hours after prasugrel loading dose
Reported as:
Least squares mean · PRU
P2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM)
PRUPlacebo and 60 mg Prasugrel-CYP2C19 EMPlacebo and 60 mg Prasugrel -CYP2C19 RM600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 EM600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 RM600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 EM600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 RM
P2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM)39.036 ± 11.39747.750 ± 30.15320.190 ± 13.16023.625 ± 21.32136.478 ± 12.57524.778 ± 20.102
Statistical analysis
  • Placebo and 60 mg Prasugrel-CYP2C19 EM vs Placebo and 60 mg Prasugrel -CYP2C19 RM · ANOVA · p = 0.7875 · Mean difference (final values): -8.714 · 95% CI -72.78 to 55.36
  • 600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 EM vs 600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 RM · ANOVA · p = 0.8913 · Mean difference (final values): -3.435 · 95% CI -53.23 to 46.37
  • 600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 EM vs 600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 RM · ANOVA · p = 0.6229 · Mean difference (final values): 11.700 · 95% CI -35.43 to 58.83

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo and 60-mg Prasugrel—2/109 (1.8%)37/109 (33.9%)
600-mg Clopidogrel and 60-mg Prasugrel—8/79 (10.1%)31/79 (39.2%)
600-mg Clopidogrel and 30-mg Prasugrel—1/88 (1.1%)31/88 (35.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
Coronary artery occlusionCardiac disorders0/1092/790/88
Acute myocardial infarctionCardiac disorders0/1091/790/88
Cardiac tamponadeCardiac disorders0/1091/790/88
Coronary artery diseaseCardiac disorders0/1091/790/88
Pericardial effusionCardiac disorders0/1091/790/88
Ventricular fibrillationCardiac disorders0/1091/790/88
HaematemesisGastrointestinal disorders0/1091/790/88
Femoral artery dissectionVascular disorders0/1091/790/88
HypotensionVascular disorders0/1091/790/88
Myocardial infarctionCardiac disorders0/1090/791/88
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPlacebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg Prasugrel
High density lipoprotein decreasedInvestigations8/1097/797/88
HypokalaemiaMetabolism and nutrition disorders6/1093/796/88
DyslipidaemiaMetabolism and nutrition disorders5/1094/792/88
HeadacheNervous system disorders3/1094/794/88
InsomniaPsychiatric disorders0/1093/790/88
HypercholesterolaemiaMetabolism and nutrition disorders4/1091/790/88
HypomagnesaemiaMetabolism and nutrition disorders3/1091/793/88
ConstipationGastrointestinal disorders3/1090/791/88
NauseaGastrointestinal disorders3/1092/792/88
Angina pectorisCardiac disorders0/1092/790/88

Baseline characteristics

Age Continuous
Age Continuous(years)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg PrasugrelTotal
Mean58.1 ± 9.4757.5 ± 9.1258.7 ± 8.0758.1 ± 8.86
Sex: Female, Male
Sex: Female, Male(Participants)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg PrasugrelTotal
Female138930
Male393941119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg PrasugrelTotal
Hispanic or Latino13141340
Not Hispanic or Latino30283088
Unknown or Not Reported95721
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg PrasugrelTotal
American Indian or Alaska Native0000
Asian1312934
Native Hawaiian or Other Pacific Islander1203
Black or African American1236
White373138106
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg PrasugrelTotal
India1011930
Argentina24410
Brazil65617
Australia1326
Canada1181029
Mexico86519
Turkey72716
United States78722
Qualifying Acute Coronary Syndrome (ACS) Event
Qualifying Acute Coronary Syndrome (ACS) Event(participants)Placebo and 60-mg Prasugrel600-mg Clopidogrel and 60-mg Prasugrel600-mg Clopidogrel and 30-mg PrasugrelTotal
Unstable Angina21162259
Non-ST-elevation Myocardial Infarction20182159
ST-elevation Myocardial Infarction1113731
08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560099, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabaad, 500 001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Delhi, 110 060, India
09

References and documents

Publications

  • Diodati JG, Saucedo JF, Cardillo TE, Jakubowski JA, Henneges C, Effron MB, Lipkin FR, Walker JR, Duvvuru S, Sundseth SS, Fisher HN, Angiolillo DJ. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost. 2014 Aug;112(2):311-22. doi: 10.1160/TH13-09-0747. Epub 2014 Apr 10. PubMed 24718367 ↗
  • Diodati JG, Saucedo JF, French JK, Fung AY, Cardillo TE, Henneges C, Effron MB, Fisher HN, Angiolillo DJ. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv. 2013 Oct 1;6(5):567-74. doi: 10.1161/CIRCINTERVENTIONS.112.000063. Epub 2013 Sep 24. PubMed 24065443 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2010
First posted
May 4, 2010
Start
May 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Oct 26, 2012
Last update
Nov 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01115738
Responsible party
Sponsor
First posted
May 4, 2010
Start date
May 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Oct 26, 2012
Last update
Nov 20, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion